Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation

Tatva Chintan reported strong financial performance for FY26 with revenue growing 32% year-on-year to Rs 5,059 million. EBITDA jumped 172% to Rs 932 million with margins expanding from 8.9% to 18.4%. PAT surged 636% to Rs 421 million with margins improving from 1.5% to 8.3%. Full-year EPS stood at Rs 17.98 versus Rs 2.44 in FY25. Q4FY26 also showed robust growth with 24% revenue increase and 902% PAT growth. Revenue mix comprised SDA (41%), PASC (32%), PTC (23%), and ESS (3%). The company operates manufacturing facilities at Ankleshwar and Dahej SEZ with combined capacity of 791 KL and 39 assembly lines. The presentation covers historical financials, product categories, manufacturing capabilities, and industry outlook.